Maxalt-mlt

   
Google
 
Web NewDrugInformation.com

Maxalt-mlt


Drug - Maxalt-mlt
The trade name of the product as shown on the labeling.

Dosage - TABLET, ORALLY DISINTEGRATING; ORAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Rizatriptan Benzoate
Multiple ingredients are in alphabetical order.

Strength - EQ 5MG BASE
The potency of the active ingredient(s), Rizatriptan Benzoate. May repeat for multiple part products.

Applicant - MERCK
The firm name holding legal responsibility for Maxalt-mlt. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 020865
The FDA assigned number to Maxalt-mlt. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Maxalt-mlt. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Jun 29, 1998
The date Maxalt-mlt was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Maxalt-mlt. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Maxalt-mlt is in. Format is RX, OTC, DISCN.

Applicant Full Name - Merck And Co Inc
The full name of the firm holding legal responsibility for the new application of Maxalt-mlt.

Maxalt-mlt